期刊
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
卷 18, 期 9, 页码 2138-2144出版社
WILEY
DOI: 10.1111/jth.15004
关键词
anticoagulant; coagulopathy; Covid-19; D-dimer; prothrombin time
Hypercoagulability is an increasingly recognized complication of SARS-CoV-2 infection. As such, anticoagulation has become part and parcel of comprehensive COVID-19 management. However, several uncertainties exist in this area, including the appropriate type and dose of heparin. In addition, special patient populations, including those with high body mass index and renal impairment, require special consideration. Although the current evidence is still insufficient, we provide a pragmatic approach to anticoagulation in COVID-19, but stress the need for further trials in this area.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据